We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.
The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".
Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.
Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.
The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".
Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.
Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.
The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".
Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.
Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.
The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".
Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.
Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.
Survival analysis data not available.
COLON ADENOCARCINOMA - Protein relative expression (CPTAC)
Number of samples
197
Samples
Sample ID
Sample type
nRPX
79097be1-cd36-4a23-99d1-3d744f_D2
Tumor
1.5
c6ae57a7-65a0-438e-bae2-97b1c8_D3
Tumor
0.9
c1b66358-d103-493c-b8ec-92c43b_D1
Tumor
0.8
c7aeb685-31b3-445e-8177-a3e729_D3
Tumor
0.7
b4dd4a04-5eda-43dd-8298-215b07_D3
Tumor
0.6
8c73f3a5-fea8-4942-90c0-966f66_D3
Tumor
0.6
642fc6c3-8d4a-4e3d-ad0a-cc088a_D2
Tumor
0.6
f635496c-0046-4ecd-89bc-7a4f33_D2
Tumor
0.5
aa0f5b40-3290-4255-8f4d-f45d4e_D3
Tumor
0.5
903d5fe0-970a-47be-a97f-3cc914_D2
Normal
0.5
01d1ffca-4235-4dfe-bf62-56f71d_D3
Tumor
0.5
f6173181-0993-4a5f-a4cd-5f30b1_D2
Tumor
0.5
5a3aa99d-ca10-45f6-939f-12392a_D2
Normal
0.5
b4e91300-405e-4239-b8da-5e1a42_D2
Tumor
0.5
ec9afcc4-ccf7-4226-b0e8-d6897d_D3
Tumor
0.4
d6584b4a-ca99-4a2a-8b4e-c8b22e_D3
Tumor
0.4
41ee934e-f7a3-4ef5-8a83-e2ac56_D2
Tumor
0.4
ea6df59d-5240-4927-b19d-d44590_D2
Tumor
0.4
21cab01c-e968-42cc-9651-1e53c0_D3
Tumor
0.4
5da00abd-5fa7-4deb-95f1-7982e0_D3
Tumor
0.4
2b810478-7956-4a8b-870d-184859_D2
Tumor
0.3
dffcac99-9eac-4717-aeb6-f4a2e7_D8
Tumor
0.3
bc574f73-89ba-44d7-992e-82622c_D3
Tumor
0.3
e196a0b4-2a05-43de-bb30-ceb761_D2
Tumor
0.3
9bf309bc-0fb6-4060-aba2-888eb3_D2
Tumor
0.3
98742d96-cc2f-43f0-9de2-bc7afe_D3
Tumor
0.3
92f7419c-c57a-4b50-bdc9-4d09ca_D2
Tumor
0.2
176d1b96-8c6e-44fe-8a32-e15194_D2
Normal
0.2
695b0b00-a86b-43c0-a6c8-50a840_D3
Tumor
0.2
f6afe41c-111d-4818-8485-fe95e0_D2
Tumor
0.2
799893aa-d523-4a08-9ea7-611cca_D3
Tumor
0.2
0f757044-9bc8-4ed4-90f3-e0a49a_D3
Tumor
0.2
0aef1fe8-ca61-4113-81d0-d82ee7_D2
Tumor
0.2
e74089a9-f78c-4ffe-8174-aef71b_D2
Normal
0.2
66b829db-1cdd-460d-b2f3-0e9ca9_D3
Tumor
0.2
e2e83b72-b14b-4b06-9461-1115d6_D2
Tumor
0.2
b605fafc-f7dd-44cc-9c86-da04e3_D2
Tumor
0.2
2666323d-522f-4f0a-823c-ff8866_D2
Normal
0.2
d0511ea6-43c3-4c61-b08e-cf49b7_D3
Tumor
0.2
1425a1a1-c835-47a2-a9b9-4db5d0_D8
Tumor
0.2
2f8b02e4-1848-4abc-a95e-dd9eb5_D3
Tumor
0.2
e8faa3a7-9fc7-428e-9334-a0afd0_D3
Tumor
0.2
4bb08fad-fa5e-471e-978b-6b09ab_D2
Tumor
0.2
526c3664-5b9b-4a2b-a00e-a14623_D2
Tumor
0.2
853ecf90-71e6-4156-a56f-a34b65_D2
Normal
0.2
5271982c-5de1-4d6e-b414-b1f3ef_D2
Tumor
0.2
803736b3-9ca9-4f9f-bdfe-8783e3_D3
Tumor
0.2
5f823547-ee16-45b7-a6a0-ef25d6_D3
Tumor
0.2
cfb4831f-e9ee-4e11-80fb-958f6f_D2
Tumor
0.1
c9730cb4-b52c-4ca8-9652-4509d0_D2
Tumor
0.1
37219a7c-6fe2-4684-a494-d0be08_D2
Tumor
0.1
2167c594-c33f-4795-b95b-69bd07_D2
Tumor
0.1
66b57abc-0d49-46bb-a390-0e11a9_D2
Tumor
0.1
8960a27e-69d8-4ec8-a795-c6cf8a_D3
Tumor
0.1
0f238226-864c-4de0-8c61-01e729_D2
Tumor
0.1
2cc46aec-6142-4fb9-aca5-c442b9_D2
Normal
0.1
04ded2cd-3b57-4aec-9c11-48f58e_D2
Normal
0.1
1fbb1add-4660-4ec1-b8c2-360f9f_D2
Normal
0.1
321fb3b2-ebb6-4ea5-b737-081264_D2
Tumor
0.1
b6b41ba2-6415-41aa-b5f5-4d47db_D2
Normal
0.1
0630ecb0-b664-4e75-bb3c-fb62ee_D3
Tumor
0.0
3765c09a-fff7-4b37-bf2b-452b23_D2
Normal
0.0
c65afd57-530c-4366-b2c8-463a46_D2
Tumor
0.0
377cdd37-d1bd-4042-997e-478a0f_D2
Normal
0.0
4cdeecb5-19fb-493c-91f5-eb0efc_D3
Tumor
0.0
b871c0c1-a97b-4ac1-887c-0317b6_D2
Normal
0.0
cd89ffbb-574a-4052-bd9a-00c890_D2
Tumor
0.0
9a6879b1-4f78-4ac6-9fca-dad049_D2
Normal
0.0
efee6bb9-69dd-46c2-85b3-b55962_D2
Normal
0.0
2d266d2d-4bb3-436c-a3e7-06acb2_D3
Tumor
0.0
c8694e31-2c8f-4eb6-a7ef-a137d9_D3
Tumor
0.0
8cc7e656-0152-4359-8566-0581c3
Tumor
0.0
bd67de01-ad7d-431a-9ad6-4dd5a1
Tumor
0.0
e14c2cbe-eca0-4745-97f6-8f27bd_D2
Normal
0.0
a2f03d85-5f1a-4b3e-9dbf-74e67e_D3
Tumor
0.0
7478980a-60fb-4f5e-aa1c-2d7941_D2
Normal
0.0
f5ed5ebc-881d-456a-80d7-42c9e7_D2
Normal
0.0
a5c8bf1d-776c-406f-82a3-2d9ce6_D2
Normal
0.0
e3c012aa-51c2-42b0-a478-bd620f_D2
Normal
0.0
42216d99-e8ff-43c9-b6db-28c3a6_D3
Tumor
0.0
cd6a4013-2958-44b9-a4f1-45c9e4_D2
Tumor
0.0
092c5a37-325b-4181-b230-2d8fff_D2
Tumor
0.0
7cc7f69f-99f5-4b23-a9e0-ba0dc8_D8
Tumor
0.0
019cd0c0-733d-4b25-90e3-d54ce0_D2
Normal
0.0
f4bccfe4-98d0-466b-a6d7-44341b_D3
Tumor
-0.1
43192517-085e-450e-9481-0a6713_D3
Tumor
-0.1
4b263734-430f-41dc-a296-8691f0_D3
Tumor
-0.1
c2c53076-b5db-4b7d-983c-a35740_D3
Tumor
-0.1
a467b905-fc0b-427b-8753-6d38dd_D3
Tumor
-0.1
206f3bd9-f62c-4663-8fdb-5b731b_D2
Normal
-0.1
58a92726-4d1f-4e44-8938-52b97d_D3
Tumor
-0.1
f69deaeb-6b6f-4c61-8900-fd0f26_D3
Tumor
-0.1
515040a4-bbfb-4a15-9e53-e7b6e6_D2
Normal
-0.1
3a17283c-a0f4-4514-956b-080d11_D2
Normal
-0.1
47d2a435-b203-4438-ae72-53c424_D2
Normal
-0.1
325b5314-6f3c-4d79-9b36-4e7ded_D2
Normal
-0.1
5557e478-3e6f-475b-8acc-1b4159_D8
Tumor
-0.1
bed27f66-ef3b-4868-b4ad-205018_D2
Normal
-0.1
d7608884-a0d6-4e9e-aac7-6cd813_D3
Tumor
-0.1
54565eae-05c5-4dae-bde9-ae4874_D2
Normal
-0.1
cbd0e774-c741-4753-9c9e-391a7d_D2
Normal
-0.1
6e20c8e9-ab75-4996-9296-445b00_D2
Tumor
-0.1
46dfc1e4-0110-4d9f-888e-6a29ab_D2
Normal
-0.1
87b0e853-43ea-4efb-8a22-dd221f_D2
Normal
-0.1
211cbcef-cb1f-4c80-a1c8-a76d3c_D2
Normal
-0.1
51590333-cfe5-4ce5-b8ff-58fa3c_D2
Normal
-0.2
5cf5e61d-21ff-4678-9126-14e9bb_D2
Normal
-0.2
da747cee-5026-4923-af63-ad9f81_D2
Normal
-0.2
05a33362-82bb-48ac-8feb-ad2ea1_D2
Tumor
-0.2
3d797911-d476-436f-9cce-33e20c_D8
Tumor
-0.2
26acb513-3ffe-49ad-8581-9dfc97_D2
Normal
-0.2
d80408d6-598d-4411-ab34-eb2545_D2
Normal
-0.2
e0068ac5-f557-443a-bd4b-bdfcef_D3
Tumor
-0.2
a243b765-61ab-4aa6-88e1-226896_D2
Normal
-0.2
92c1ebb5-ac1d-4bf5-a14f-516e1d_D3
Tumor
-0.2
1ab06c24-ffc0-4323-a0cc-e9f5c5_D2
Tumor
-0.2
b2978e90-cd2a-4665-b1bf-508a99_D2
Normal
-0.2
067db520-1b1f-4569-9414-e37a6e_D2
Normal
-0.2
62627b73-1763-48bc-8eea-e5bd76_D2
Normal
-0.2
76498650-fdbf-4f5d-a19a-cce9a2_D2
Normal
-0.3
cd3a9d59-bf13-48f3-ae97-bdbca4_D2
Normal
-0.3
0065bfd9-e1b9-43a8-9379-9658ba_D3
Tumor
-0.3
7784e2e5-c0e1-4b85-8cc1-7faac8_D2
Normal
-0.3
5de06adb-e00d-4114-8d76-04bd30_D2
Normal
-0.3
6b0a3188-d8ca-4d50-a377-a8fe4c_D2
Normal
-0.3
6e0d04fc-e6a8-41ed-b6f3-45537d_D2
Normal
-0.3
5c70e654-583c-4dd3-ad42-0d9b39_D2
Normal
-0.3
e1cd3d70-132b-452f-ba10-026721_D2
Tumor
-0.3
8fab37a4-cdf9-4ce8-9081-7b9148_D2
Normal
-0.3
dfdf03a6-c324-4d8c-a909-ea7345_D2
Tumor
-0.3
23e938d0-92b8-4aea-90c1-4385df_D2
Normal
-0.3
fc9b09af-23b8-4ffe-b6c6-41236d_D2
Normal
-0.3
db3f5ad9-d14d-4126-a3e7-d80faa_D3
Tumor
-0.3
233ec093-9a30-4ef4-a12c-91757e_D2
Normal
-0.3
1c070992-647b-4173-a481-904c4d_D2
Normal
-0.4
1136008b-97ce-49b0-bf24-abbea6_D2
Normal
-0.4
722378ea-d1a7-4cfc-aca5-ba45f9_D8
Tumor
-0.4
1bf00d93-240f-47e8-8055-f546b0_D2
Normal
-0.4
359f5c81-2575-497e-8630-e4866f_D2
Normal
-0.4
8af80ae9-2088-4124-91fb-8d6c17_D3
Tumor
-0.4
41a04113-2061-4923-bca5-da586c_D2
Normal
-0.4
5e886f1c-8165-4232-9591-d80799_D2
Normal
-0.4
a313f6ef-5994-4d49-9e66-c26911_D2
Normal
-0.4
1f79fed9-f0d4-4c45-acd2-ea1441_D2
Normal
-0.4
963fc8db-f412-4427-a198-23f660_D2
Normal
-0.4
8980bb9d-65c1-41cb-9f90-dddd5f_D2
Normal
-0.4
d8805fa4-30f9-4417-907e-fdc50c_D2
Normal
-0.4
43bc845e-d22e-4c10-b3e8-bc54e6_D2
Normal
-0.4
c9f0f144-47f3-4d64-b29f-bcedfa_D2
Normal
-0.4
da95f6f8-be46-4ed8-a493-2c99f0_D2
Normal
-0.5
b3696374-c6c0-49dd-833e-596e26_D2
Normal
-0.5
87408d9e-4029-4e8f-b14c-8efc04_D3
Tumor
-0.5
694e8df1-d9ee-473b-bec1-4f9237_D2
Normal
-0.5
0d5554d1-1653-4589-a44f-43113e_D2
Normal
-0.5
d3078fa8-0692-411f-8441-0c7c48_D8
Tumor
-0.5
154115ac-2ec2-439d-b55e-0464ee_D2
Normal
-0.5
e070ff10-058b-4733-93ab-bdd702_D2
Normal
-0.5
65867ab1-5eab-44a8-b2bb-d27263_D2
Normal
-0.5
16ac8458-5200-4302-9ad0-b311df_D2
Normal
-0.5
a84149b1-8453-45f0-8400-d7b12f_D2
Normal
-0.5
4c9dcc8c-ccdc-4336-8e23-107feb_D2
Normal
-0.5
df479b07-bbf6-472d-a580-c3fd0c_D2
Normal
-0.5
9a48cf57-e1f0-4ea1-9804-d563f2_D2
Normal
-0.5
591fb460-703a-437d-8d9a-ff2a35_D3
Tumor
-0.5
7bdfa5c9-d11f-4600-9c44-a87996_D2
Normal
-0.5
411d9597-c785-4de5-b449-29a80d_D2
Normal
-0.5
c307b7b0-534a-45fa-a420-35f773_D2
Normal
-0.5
f9d6fb1b-988e-4D88-9272-cc672f_D8
Tumor
-0.5
5347d2ce-df0c-4d81-a3e2-22db11_D2
Normal
-0.5
bda3787a-1397-4716-bb17-4992a8_D2
Normal
-0.5
6d9f8b06-f28c-4e9b-823b-33ebb7_D2
Normal
-0.5
573048dd-2502-40e0-8e8c-c41bb8_D3
Tumor
-0.5
372c900a-fced-4eef-9dc4-7282ec_D2
Tumor
-0.5
6797a69d-2f74-44b9-8147-cd4fac_D2
Normal
-0.6
1563ef63-d2e6-406f-adc1-255949_D3
Tumor
-0.6
0c330883-ab58-4a5a-bff7-07d283_D2
Normal
-0.7
88c621d7-7fb3-4825-abbe-82ae4c_D2
Normal
-0.7
820a3f08-5bb1-44b3-a133-ee167e_D2
Tumor
-0.7
64ed43a2-f083-43cb-9d0d-118495_D2
Normal
-0.7
b2400046-1d25-429d-a821-6040a6
Tumor
-0.7
63c1f7ac-b1ae-4c28-95aa-ce21e5_D2
Normal
-0.8
3e8019e8-125f-4615-a1fa-a448e9_D2
Normal
-0.8
02cde0c0-6840-495b-9b11-007d82_D2
Normal
-1.0
e515eb5c-8005-416a-9b42-59de9d_D8
Tumor
-1.0
cc271b3d-ed33-481f-9d23-15f2f6_D2
Normal
-1.1
0784c7b3-e6a4-42a8-9288-eb4ba0_D2
Normal
-1.1
348f6009-e1be-44d2-a093-9ca844_D2
Normal
-1.3
82157a70-12f1-4913-b548-d98881_D2
Normal
-1.3
a90eb718-6a8f-4cbf-89c1-f9e9bd_D2
Tumor
N/A
8b9e4266-7754-4f2c-ac9e-329905_D2
Tumor
N/A
7fd386f0-e7f6-4ee1-9cd7-b3318a_D2
Normal
N/A
f6b1079b-9d67-4c63-b3d0-d562b5_D2
Tumor
N/A
71b2c1cc-0a31-4ca8-8beb-251e17_D2
Normal
N/A
974e136f-7020-4a38-b9c1-094df9_D2
Normal
N/A
a27cf22d-836e-49a7-802f-47c1db_D2
Normal
N/A
7fd2eea8-bf99-4f97-8b9e-fb703f_D2
Normal
N/A
059a7065-3a5f-4eea-97e5-85ab01_D2
Normal
N/A
Show allShow less
COLORECTAL CANCER - Protein expressioni
A mouse-over function shows sample information and annotation data. Click on an image to view it in a full screen mode. Samples can be filtered based on level of antibody staining by selecting one or several of the following categories: high, medium, low and not detected. The assay and annotation is described here.
Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.
Antibody stainingi
Antibody staining in the annotated cell types in the current human tissue is reported as not detected, low, medium, or high, based on conventional immunohistochemistry profiling in selected tissues. This score is based on the combination of the staining intensity and fraction of stained cells.
Each image is clickable and will lead to virtual microscopy that enables deeper exploration of all samples and also displays staining intensity scores, fraction scores and subcellular localization as well as patient and tissue information for each sample.